Crinetics Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q1 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Crinetics Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2019 to Q3 2024.
  • Crinetics Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 13.3 %, a 8.29% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 13.3 -1.2 -8.29% Sep 30, 2024
Q2 2024 14.3 +2.43 +20.5% Jun 30, 2024
Q1 2024 15 +4.61 +44.4% Mar 31, 2024
Q4 2023 16.2 +6.25 +62.7% Dec 31, 2023
Q3 2023 14.5 +5.85 +67.8% Sep 30, 2023
Q2 2023 11.8 +3.54 +42.7% Jun 30, 2023
Q1 2023 10.4 +2.57 +32.9% Mar 31, 2023
Q4 2022 9.96 +2.61 +35.5% Dec 31, 2022
Q3 2022 8.63 +0.24 +2.86% Sep 30, 2022
Q2 2022 8.29 +0.2 +2.47% Jun 30, 2022
Q1 2022 7.82 -0.09 -1.14% Mar 31, 2022
Q4 2021 7.35 -1.26 -14.6% Dec 31, 2021
Q3 2021 8.39 -0.73 -8.01% Sep 30, 2021
Q2 2021 8.09 -1.95 -19.4% Jun 30, 2021
Q1 2021 7.91 -3.09 -28.1% Mar 31, 2021
Q4 2020 8.6 -1.31 -13.2% Dec 31, 2020
Q3 2020 9.12 +0.29 +3.28% Sep 30, 2020
Q2 2020 10 +2.36 +30.7% Jun 30, 2020
Q1 2020 11 +1.86 +20.3% Mar 31, 2020
Q4 2019 9.91 Dec 31, 2019
Q3 2019 8.83 Sep 30, 2019
Q2 2019 7.68 Jun 30, 2019
Q1 2019 9.15 Mar 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.